PF-06648671

PF-06648671 is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM) . PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer’s disease[1].

Product Specifications

CAS Number

[1587727-31-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

γ-secretase

Type

Reference compound

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pf-06648671.html

Purity

98.88

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

FC(F)(C(C=C1Cl)=C([C@](CC2)([H])O[C@]2([H])[C@@H](N(CCN3C4=CC=C(N5C=NC(C)=C5)C3=O)C4=O)C)C=C1F)F

Molecular Formula

C25H23ClF4N4O3

Molecular Weight

538.92

Precautions

H302, H315, H319

References & Citations

[1]Jae Eun Ahn, et al. Pharmacokinetic and Pharmacodynamic Effects of a γ-Secretase Modulator, PF-06648671, on CSF Amyloid-β Peptides in Randomized Phase I Studies. Clin Pharmacol Ther 2020 Jan;107 (1) :211-220.